Abstract
Comparative genomic hybridization (CGH) was employed to study chromosomal aberrations in relation to cell proliferation, apoptosis, and patient survival in 94 cases of B-cell non-Hodgkin’s lymphoma diagnosed between 1983 and 1993. Eighty cases had aberrations by CGH. Chromosomal regions 1p21–31.1 (10%), 6cen-q24 (12%), 8p (11%), 9p21-ter (14%), 11q21–23.1 (11%), 13q13–21.1 (12%), and 17p (15%) were frequently lost. Gains were found at 3q21-ter (22%), 6p (11%), 7p (12%), 8q23-ter (13%), 12cen-q15 (17%), 17q24-ter (13%), and 18q13.3–21 (20%). A high number of aberrations (≥ 4, 33 cases) was associated (P ≤ 0.001) with the mantle cell and diffuse large B-cell lymphoma subtypes, a high fraction of tumour cells in S phase, and short survival (RR (relative risk) = 3.7). Loss of 1p21–31.1, 8p, 9p21-ter, 11q21–23.1, and 13q13–21.1 were associated with mantle cell lymphoma (P ≤ 0.03), while gain of 6p and 12cen-q15 were more frequent in diffuse large B-cell and small lymphocytic lymphoma, respectively (P = 0.04). Loss of 8p and 17p, and gain of 3q21-ter, 6p, 7p, and 8q23-ter were associated with a high S phase fraction (P ≤ 0.03), but none of the aberrations were associated with tumour apoptotic fraction (P ≥ 0.13). The most important prognostic CGH parameters (P < 0.001) were losses of 11q21–23.1 (RR = 3.8) and 17p (RR = 4.4), and gain of 6p (RR = 4.2). The latter parameters and IPI were the only ones with independent prognostic value (RR = 10, 5.0, 6.7, and 3.7, respectively; P < 0.001) when assessed together with lymphoma sub-type, primary versus relapse cases, treatment, B symptoms, S phase fraction, and presence of BCL1 and BCL2 translocations. A combined CGH/IPI binary parameter had high prognostic value for patients receiving different treatments, with various lymphoma sub-types, and for primary as well as relapse cases. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Autio K, Aalto Y, Franssila K, Elonen E, Joensuu H and Knuutila S (1998) Low number of DNA copy number changes in small lymphocytic lymphoma. Haematologica 83: 690–692
Beà S, Ribas M, Hernandez JM, Bosch F, Pinyol M, Hernandez L, Garcia JL, Flores T, Gonzalez M, Lopez-Guillermo A, Piris MA, Cardesa A, Montserrat E, Miro R and Campo E (1999) Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93: 4365–4374
Bentz M, Huck K, Manoir S, Joos S, Werner CA, Fischer K, Döhner H and Lichter P (1995) Comparative genomic hybridization in chronic B-cell leukemias shows a high incidence of chromosomal gains and losses. Blood 85: 3610–3618
Bentz M, Werner CA, Döhner H, Joos S, Barth TFE, Siebert R, Schroder M, Stilgenbauer S, Fischer K, Moller P and Lichter P (1996) High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma. Blood 88: 1437–1444
Bentz M, Plesch A, Bullinger L, Stilgenbauer S, Ott G, Muller-Hermelink HK, Baudis M, Barth TF, Moller P, Lichter P and Döhner H (2000) t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 27: 285–294
Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, Keating M, Albitar M, Reed JC and Croce CM (1999) ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 59: 24–27
Carbone PP, Kaplan HS, Musshoff K, Smithers DW and Tubiana H (1971) Report of the Committee of Hodgkin’s disease staging classification. Cancer Res 31: 1860–1861
DeAngelis P, Clausen OPF, Schjølberg A and Stokke T (1999) Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes. Br J Cancer 80: 526–535
Dierlamm J, Rosenberg C, Stul M, Pittaluga S, Wlodarska I, Michaux L, Dehaen M, Verhoef G, Thomas J, de Kelver W, Bakker-Schut T, Cassiman JJ, Raap AK, De Wolf-Peeters C, Van den Berghe H and Hagemeijer A (1997) Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization. Leukemia 11: 747–758
Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J and Stilgenbauer S (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85: 1580–1589
Dohner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M, Fischer K, Hunstein W and Lichter P (1997) 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 89: 2516–2522
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M and Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910–1916
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA and Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328: 1002–1006
Galteland E, Holte H and Stokke T (1999) c-MYC, RB-1, and TP53 copy number in B-cell Non-Hodgkin’s Lymphoma assessed by dual-color fluorescence in situ hybridization. Cytometry 38: 53–60
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf Peeters C, Falini B and Gatter KC (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84: 1361–1392
Heim S and Mitelman F (1995). Cancer cytogenetics, Second Edn. pp. 237–309, Wiley-Liss: New York
Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA, Piris MA, Montserrat E, Cardesa A, Jaffe ES, Campo E and Raffold M (1996) p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87: 3351–3359
Kallioniemi O-P, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW and Pinkel D (1994a) Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10: 231–243
Kallioniemi A, Kallioniemi O-P, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW and Waldman FM (1994b) Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. PNAS 91: 2156–2160
Knutsen T (1998) Cytogenetic changes in the progression of lymphoma. Leuk Lymphoma 31: 1–19
Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323–331
Mitelman F, Kaneko Y and Berger R (1994) Report of the committee on chromosome changes in neoplasia. In: Human gene mapping 1993, Cuticchia AJ and Pearson PL (eds) pp. 773 John Hopkins: Baltimore, MD
Mitelman F, Mertens F and Johansson B (1997) A breakpoint map of recurrent chromosomal rearrangements ain human neoplasia. Nature Genetics special issue, 417–474
Monni O, Joensuu H, Franssila K and Knuutila S (1996) DNA copy number changes in diffuse large B-cell lymphoma-comparative genomic hybridization study. Blood 87: 5269–5278
Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K and Knuutila S (1997) Bcl-2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 90: 1168–1174
Monni O, Oinonen R, Elonen E, Franssila K, Teerenhovi L, Joensuu H and Knuutila S (1998) Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer 21: 298–307
Offit K (1992) Chromosome analysis in the management of patients with Non-Hodgkin’s lymphoma. Leukemia Lymphoma 7: 275–282
Ong ST and Le Beau MM (1998) Chromosomal abnormalities and molecular genetics of Non-Hodgkin’s lymphoma. Semin Oncol 25: 447–460
Panayiotidis P and Kotsi P (1999) Genetics of small lymphocyte disorders. Semin Hematol 36: 171–177
Pui CH and Evans WE (1998) Acute lymphoblastic leukemia. N Engl J Med 339: 605–615
Rabbitts TH (1994) Chromosomal translocations in human cancer. Nature 372: 143–149
Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES and Raffeld M (1993) p53 mutation is associated with progression in follicular lymphomas. Blood 82: 1994–2004
Schaffner C, Idler I, Stilgenbauer S, Döhner H and Lichter P (2000) Mantle cell lymphoma is characterized by inactivation of the ATM gene. PNAS 97: 2773–2778
Schoch C, Rieder H, Stollmann-Gibbels B, Freund M, Tischler HJ, Silling-Engelhardt G and Fonatsch C (1995) 17p anomalies in lymphoid malignancies: diagnostic and prognostic implications. Leuk Lymphoma 17: 271–279
Schouten HC, Sanger WG, Weisenburger DD, Anderson J and Armitage JO (1990) Chromosomal abnormalities in untreated patients with non-Hodgkin’s lymphoma: associations with histology, clinical characteristics, and treatment outcome. Blood 75: 1841–1847
Sherr CJ (1996) Cancer cell cycles. Science 274: 1672–1677
Stokke T, Holte H, Smedshammer L, Smeland EB, Kaalhus O and Steen HB (1998a) Proliferation and apoptosis in malignant and normal cells in B-cell Non-Hodgkins lymphomas. Br J Cancer 77: 1832–1838
Stokke T, Smeland EB, Kvaløy S and Holte H (1998b) Tumor cell proliferation, but not apoptosis, predicts survival in B-cell Non-Hodgkins lymphomas. Br J Cancer 77: 1839–1841
Stokke T, Galteland E, Holte H, Smedshammer L, Suo Z, Smeland EB, Børresen-Dale A-L, DeAngelis P and Steen HB (2000) Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor survival in B cell Non-Hodgkin’s lymphoma. Int J Cancer 89: 313–324
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329: 987–994
Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, Kunlin A, Monconduit and Bastard C (1994) Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84: 1043–1049
Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J and Kallioniemi O-P (1998) Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosom Cancer 21: 177–184
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Stokke, T., DeAngelis, P., Smedshammer, L. et al. Loss of chromosome 11q21–23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin’s lymphoma. Br J Cancer 85, 1900–1913 (2001). https://doi.org/10.1054/bjoc.2001.2164
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2164
Keywords
This article is cited by
-
Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma
Oncogene (2008)
-
Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma
Journal of Hematopathology (2008)
-
A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation
Leukemia (2007)
-
Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas
Leukemia (2006)
-
Heterogeneous Abnormalities of CCND1 and RB1 in Primary Cutaneous T-Cell Lymphomas Suggesting Impaired Cell Cycle Control in Disease Pathogenesis
Journal of Investigative Dermatology (2006)